UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Antiviral treatment for COVID-19: the evidence supporting remdesivir.

Richardson, C; Bhagani, S; Pollara, G; (2020) Antiviral treatment for COVID-19: the evidence supporting remdesivir. Clinical Medicine , 20 (6) e215-e217. 10.7861/clinmed.2020-0524.

[img] Text
clinmed-20-6-e215.pdf - Published version
Access restricted to UCL open access staff until 17 November 2021.

Download (166kB)

Abstract

The emergence of the novel beta coronavirus SARS-CoV-2 and the ensuing COVID-19 pandemic has generated a rapidly evolving research landscape in the search for new therapeutic agents. The intravenous antiviral drug remdesivir has in vitro activity against SARS-CoV-2 and now studies have reported its clinical efficacy, demonstrating shorter time to recovery in hospitalised patients with severe COVID-19. Adverse event rates were low and remdesivir has now received conditional marketing authorisation from the European Medicines Agency. An interim clinical commissioning policy is in place in the UK. These studies make remdesivir the first antiviral drug able to alter the natural history of severe COVID-19, and a benchmark for the comparison of new therapies in the future. Ongoing studies are investigating its use in early mild/moderate COVID-19, alternative formulations, and the combination of remdesivir with immunomodulatory agents.

Type: Article
Title: Antiviral treatment for COVID-19: the evidence supporting remdesivir.
Location: England
DOI: 10.7861/clinmed.2020-0524
Publisher version: https://doi.org/10.7861/clinmed.2020-0524
Language: English
Additional information: This version is the version of record. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: COVID-19, antiviral, remdesivir, Adenosine Monophosphate, Administration, Intravenous, Alanine, Antiviral Agents, Betacoronavirus, COVID-19, Coronavirus Infections, Female, Humans, Male, Middle Aged, Pandemics, Pneumonia, Viral, Randomized Controlled Trials as Topic, SARS-CoV-2
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
URI: https://discovery.ucl.ac.uk/id/eprint/10131584
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item